May 19, 2016
Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy
Lung cancer is the second-most common type of cancer in the United States, including approximately 235,000 new cases each year, 84% of which are non–small-cell lung cancer (NSCLC). Although lung cancer remains the leading cause of cancer mortality—outweighing prostate, breast, and colon cancer combined—advances in treatment are improving patient outcomes and decreasing mortality.
Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy
Jonathan Wesley Riess, MD, MS Medical Director of Thoracic Oncology Associate Professor, Hematology and Oncology University of California UC Davis Comprehensive Cancer Center Sacramento, CA Introduction Lung cancer is the second-most common type of cancer in the United States, including approximately 235,000 new cases each year, 84% of which are [ Read More ]